Smoking Cessation Health Center

Font Size
A
A
A

Smoking-Cessation Aids Beat Cold Turkey

Drugs and Nicotine-Replacement Therapies Better Than Placebo at Smoking Cessation
By Jennifer Warner
WebMD Health News
Reviewed by Louise Chang, MD

July 14, 2008 -- Smoking-cessation drugs and many nicotine-replacement therapies are more than twice as effective at helping smokers quit than going it alone.

A new analysis of 69 studies comparing seven different smoking-cessation treatments shows six of the seven treatments were more effective than placebo in helping smokers quit the habit for at least six months to a year.

But researchers say smoking-cessation therapies are underused because of problems translating those results to the public and providing widespread access to the treatments.

"We are confident that the recommended treatments will substantially increase rates of smoking abstinence when given to smokers who wish to quit," researcher John Cunningham of Toronto's Centre for Addiction and Mental Health, says in a news release. 

For example, Cunningham says these results suggest that offering free nicotine-replacement therapy to adults who want to quit smoking could provide major public health benefits.

(What do recommend for quitting? Share your story on WebMD's Smoking Cessation support group.)

Helping Smokers Quit

In the study, published in the Canadian Medical Association Journal, researchers compared 69 clinical trials on smoking- cessation therapies involving nearly 33,000 people.

The results showed six therapies were more effective than placebo at helping smokers quit, including:

  • Chantix (2.4 times more effective than placebo)
  • Nicotine nasal spray (2.37)
  • Zyban (also known as Wellbutrin) (2.07)
  • Nicotine patch (2.07)
  • Nicotine tablet (2.06)
  • Nicotine gum (1.71)

Although the findings also favored the effectiveness of the nicotine inhaler over placebo, the results were not conclusive.

In a related article in the same journal, Canadian researchers randomly surveyed 825 smokers and asked them if they would be interested in receiving free nicotine-replacement therapy and how they would use it. Nearly 60% of smokers said they would be interested in receiving free nicotine-replacement therapy, and 94% of the interested smokers said they would use it to quit smoking for good.

In fact, researchers found smokers who were interested in quitting smoking for good were more interested in using nicotine-replacement therapy than those who planned to cut back or maintain their smoking habits.

Experts say these results suggest that new strategies to inform smokers who want to quit about their options may be needed to improve use of smoking-cessation therapies.

"Because of a powerful multinational tobacco industry, the need to prevent death and disability from tobacco-related illnesses will not disappear,” writes J. Taylor Hayes, MD, of the Mayo Clinic in a commentary in the same journal. "However, we have effective treatments to assist smokers at their attempts to live free of tobacco. The success of our efforts hinges on our ability to place these products in the hands of people who need them."

webMD Video

Show or hide information about video: Stop Smoking   Stop Smoking

48x48_stop_smoking.jpg

Isadore Rosenfeld talks about ways to stop smoking.

Watch Video: Stop Smoking (opens in a new window)

Show or hide information about video: Quit Smoking Aids   Quit Smoking Aids

Show or hide information about video: How to Quit Smoking   How to Quit Smoking

Show or hide information about video: Alcohol, Nicotine Connection   Alcohol, Nicotine Connection

Show or hide information about video: Green Tea Science   Green Tea Science

Advertise on Fox News Channel, FOXNews.com and FOX News Radio Jobs at FOX News Channel. Internships at FOX News Channel (now accepting Fall interns).
Terms of use. Privacy Statement. For FOXNews.com comments write to foxnewsonline@foxnews.com; For FOX News Channel comments write to comments@foxnews.com
© Associated Press. All rights reserved.
SMARTMONEY ® © 2006 SmartMoney. SmartMoney is a joint publishing venture of Dow Jones & Company, Inc. and Hearst SM Partnership. All Rights Reserved.
All quotes delayed by 20 minutes. Delayed quotes provided by ComStock.
Historical prices and fundamental data provided by Hemscott, Inc.
Mutual fund data provided by Lipper. Mutual Fund NAVs are as of previous day's close.
Earnings estimates provided by Zacks Investment Research.
Upgrades and downgrades provided by Briefing.com.
This material may not be published, broadcast, rewritten, or redistributed. © 2006 FOX News Network, LLC. All rights reserved. All market data delayed 20 minutes.